$300M research fund will focus on Alzheimer’s

The National Institutes on Aging (NIA), part of the National Institutes of Health, is launching a $300 million research fund focused on Alzheimer’s disease.

The research fund aims to track the health of Americans for decades, with the intent of housing the long-term health information of 70% to 90% of the population. The news was first reported by Reuters.

NIA will fund the project, with the platform using data from medical records, insurance claims, pharmacies, mobile devices, sensors and various government agencies. By tracking health data, researchers are hopeful to make advancements in Alzheimer’s with the health information of patients before and after they are diagnosed. For example, Alzheimer’s symptoms can be seen up to 20 years before memory issues arise.

Ideally, the database will help identify healthy people at risk for Alzheimer’s, which impacts six million Americans. These identified people could be eligible for drug trials.

"Real-world data is what we need to make a lot of decisions about the effectiveness of medications and looking really at a much broader population than most clinical trials can cover," Nina Silverberg, PhD, director of the NIA's Alzheimer's Disease Research Centers program, told Reuters.

The fund comes at a time when research around Alzheimer’s disease has renewed hope with the development of Leqembi, a new treatment from Eisai and Biogen that slows the advancement of the disease in early-stage patients.

See the full story below:

 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”